Vincerx Pharma, Inc. (VINC)
NASDAQ: VINC · IEX Real-Time Price · USD
0.869
+0.019 (2.24%)
Apr 22, 2024, 4:00 PM EDT - Market closed
Vincerx Pharma Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Vincerx Pharma.
Analyst Consensus: Buy
Analyst Ratings
According to 1 stock analyst, the rating for Vincerx Pharma is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $5 | Buy | Reiterates | $5 | +475.37% | Sep 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +245.22% | Nov 17, 2022 |
| SVB Leerink | SVB Leerink | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +475.37% | Aug 12, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.05
from -1.89
EPS Next Year
-0.96
from -1.05
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 913,500 | 7.9M | 25.9M |
| Avg | n/a | n/a | 887,400 | 7.7M | 25.2M |
| Low | n/a | n/a | 852,600 | 7.4M | 24.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 793.4% | 236.8% |
| Avg | - | - | - | 767.8% | 227.2% |
| Low | - | - | - | 733.8% | 214.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.78 | -0.81 | -1.08 | -0.89 | -0.78 |
| Avg | -1.05 | -0.96 | -1.05 | -0.87 | -0.75 |
| Low | -1.28 | -1.09 | -1.01 | -0.83 | -0.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.